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Summary
Purpose: Lamotrigine (LTG), vigabatrin (VGB) and gabapentin (GBP) are three anti-
epileptic drugs (AEDs) used in the treatment of children with epilepsy for which long-
term retention rates are not currently well known. This study examines the efficacy,
long-term survival and adverse event profile of these three agents used as add-on
therapy in children with refractory epilepsy over a 10-year period.
Methods: Three separate audits were conducted between February 1996 and Sep-
tember 2000. All children studied had epilepsy refractory to other AEDs. Efficacy was
confirmed if a patient became seizure free or achieved >50% reduction in seizure
frequency for 6 months or more after starting therapy. Adverse events and patient
survival for each drug were recorded at the end of the study period.
Results: Between September 1990 and February 1996, 132 children received LTG, 80
VGB and 39 GBP. At the 10-year follow-up audit, 33% of the children on LTG had a
sustained beneficial effect on their seizure frequency in contrast to 19% for VGB and
15% for GBP. No significant difference in efficacy was found in children with partial
seizures. Children with epileptic encephalopathy (EE) including myoclonic-astatic
epilepsy and Lennox—Gastaut Syndrome (LGS) achieved a more favorable response to
LTG. The main reasons for drug withdrawal were lack of efficacy for VGB, apparent
worsening of seizures for GBP and the development of a rash for LTG.
Conclusions: Lamotrigine is a useful add-on therapy in treating children with epi-
lepsy. It has a low adverse event profile and a sustained beneficial effect in children
with intractable epilepsy.
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Three anti-epileptic agents, lamotrigine (LTG), vig-
abatrin (VGB) and gabapentin (GBP) provided new
add-on drug treatment options for children with
refractory epilepsy during the last decade. While
numerous studies have examined the safety and
efficacy of these agents, there have been few
reporting an observation period longer than 4
years.1 Our study aimed to report the efficacy and
adverse event profile of these three anti-epileptic
drugs (AEDs) as add-on therapy since they were first
licensed for paediatric use in the Republic of Ire-
land. Survival data for lamotrigine and vigabatrin
over a 10-year period and for gabapentin over a 6-
year period was obtained.Methods
A retrospective chart review audit was performed
by convenience sampling on patients attending a
Children’s Seizure Disorder Clinic with refractory
epilepsy who were treated with LTG, VGB or GBP
as add-on therapy. The initial audit was conducted
between February and October 1996. This was
repeated between January and November 1998
and again in September 2000. Patients were classi-
fied into partial and generalized seizures. The latter
group also consisted of a subgroup of children with
epileptic encephalopathy (EE) characterized by
multiple seizure types, including drop seizures,
clinical evidence suggesting intellectual deteriora-
tion due to seizures and slow background with slow
spike-wave discharges on EEG. The term myoclonic
epilepsy has also been used to define this hetero-
genous group of patients with polymorphous sei-
zures. Our cases included some children with
Lennox—Gastaut Syndrome and myoclonic-astatic
epilepsy but many could not be classified into a
specific epileptic syndrome. For the purpose of this
study, we grouped these patients together and
designated them as the epileptic encephalopathy
(EE) group. All children had been refractory to other
standard AEDs at the time of initiation of add-onTable 1 Initial efficacy of lamotrigine, vigabatrin and gab
Seizure type Generalized Partial
No. of
cases
Sz
free (%)
50%
red. (%)
No. of
cases
Lamotrigine 30 3 (10) 9 (30) 46
Vigabatrin 18 2 (11) 1 (5) 46
Gabapentin 5 0 0 26
50% red: equal or more than 50% reduction of seizure frequency;therapy. Cases were considered refractory if the
patient failed to achieve reduction in seizure fre-
quency in response to two or more first line AEDs as
judged by doctor or parents. Approval for this study
was obtained from the hospital’s Ethics Committee.
All patients were assessed with regard to the type
and duration of epilepsy, seizure frequency, anti-
epileptic drug (AED) exposure and history of adverse
events.
An AED given as add-on therapy was regarded as
efficacious if a child became seizure free or had a
greater than 50% reduction in seizure frequency
within the initial 6-month period. Children who
maintained this efficacious response beyond the
initial 6-month period were regarded as having
achieved sustained benefit. Seizure frequency and
adverse events were reassessed during subsequent
audits in 1998 and 2000. Where the add-on therapy
had been withdrawn for any reason, the duration of
time on that particular therapy was recorded. This
data was analyzed statistically and Kaplan—Meier
survival curves for the 10-year period were con-
structed.Results
A total of 176 cases were analyzed during our study
period. There were 79 male and 97 female patients.
The age at onset of epilepsy ranged from 1 month to
12 years (mean = 3.3 years). There were 73 children
with intractable partial seizures, 42 had generalized
seizures including absences and there were 61 in the
EE group. AEDs used in this study as add-on therapy
included LTG 132 (53%), VGB 80 (32%) and GBP 39
(15%).
Children with refractory epilepsy in our clinic
were first prescribed VGB in February 1990, LTG
in September 1990 and GBP in April 1994. Patients
who achieved either seizure freedom or greater
than 50% reduction in seizure frequency 6 months
after initiation of an add-on AED are recorded
(Table 1). On follow-up, some patients for whom
therapy was initially efficacious remained on treat-
ment in the absence of a clear sustained benefit.apentin.
EE
Sz
free (%)
50%
red. (%)
No. of
cases
Sz
free (%)
50%
red. (%)
9 (20) 6 (13) 56 11 (20) 9 (16)
7 (15) 10 (22) 16 1 (6) 1 (6)
2 (8) 6 (23) 8 0 0
Sz free: seizure free over a period of at least 6 months.
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Table 2 Sustained beneficial effect of lamotrigine, vigabatrin and gabapentin.
Seizure type Generalized Partial EE
Continued
on Rx. (%)
Sustained
benefit (%)
Continued
on Rx. (%)
Sustained
benefit (%)
Continued
on Rx. (%)
Sustained
benefit (%)
Lamotrigine 14 (47) 11 (37) 21 (46) 15 (33) 28 (50) 18 (32)
Vigabatrin 2 (11) 2 (11) 12 (26) 12 (26) 3 (19) 1 (6)
Gabapentin 0 0 8 (31) 7 (27) 2 (25) 0
Sustained benefit: equal or more than 50% reduction of seizure frequency or seizure free over a period of at least 6 months or more.
Figure 1 Kaplan—Meier survival curve for all seizure
groups; ‘‘lamotrigine 1’’ shows the survival curve for
patients who take lamotrigine; ‘‘lamotrigine 0’’ shows
the survival curve for all other patients.
Figure 3 Kaplan—Meier survival curve for partial sei-
zures; ‘‘lamotrigine 1’’ shows the survival curve for
patients who take lamotrigine; ‘‘lamotrigine 0’’ shows
the survival curve for all other patients.These were patients for whom control had always
been difficult and whose carers were reluctant to
permit further changes in treatment. We have
extracted these patients and recorded the number
with an apparent sustained beneficial effect from
their add-on therapy in a separate column (Table 2).
Kaplan—Meier curves were constructed to illus-
trate survival rates over the study period (Figs. 1—4).
These curves represent all patients remaining onFigure 2 Kaplan—Meier survival curve for Epileptic
encephalopathy group; ‘‘lamotrigine 1’’ shows the survival
curve for patients who take lamotrigine; ‘‘lamotrigine 0’’
shows the survival curve for all other patients.treatment rather than those remaining on treatment
with sustained beneficial effect. The data shows LTG
to be the most effective of the three add-on AEDs
withpatient survival onLTGexceeding that forVGBor
GBP. Children who became seizure free remained on
the same therapy combination or had some of their
AED’s reduced or withdrawn depending on their
degree of seizure control. No patient was weaned
to mono-therapy during the study period.Figure 4 Kaplan—Meier survival curve for generalized
seizures; ‘‘lamotrigine 1’’ shows the survival curve for
patients who take lamotrigine; ‘‘lamotrigine 0’’ shows
the survival curve for all other patients.
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Table 3 Adverse effects profile, lamotrigine, vigabatrin and gabapentin.
Adverse effects Lamotrigine no. (%) Vigabatrin no. (%) Gabapentin no. (%)
Rash 11 (8) 0 0
Behavior change 6 (4.5) 6 (7.5) 5 (13)
Weight gain 0 1 (1) 0
Headache 1 (0.8) 0 2 (5)
" Seizure frequencya 2 (1.5) 3 (4) 17 (44)
Drug toleranceb 0 8 (10) 0
Visual field defects 0 2 (2.5) 0
Lack of efficacyc 50 (38) 38 (48) 8 (21)
a Increase in seizure frequency from baseline after initiation of add-on therapy.
b Initial beneficial effect lost despite increasing doses of add-on AED.
c No change in seizure frequency from that at the time of initiation of therapy.We observed a number of adverse effects neces-
sitating withdrawal of the add-on therapy over the
study period (Table 3). LTG was the best tolerated
with adverse events occurring in 14.5% of patients
when lack of efficacy was excluded. The most com-
mon adverse event was the development of a rash
prompting an immediate withdrawal of LTG. How-
ever, reintroduction of LTG at a lower dose was
tolerated in a few cases. Excluding lack of efficacy,
25% of patients on VGB and 62% of those on GBP
experienced adverse events. Drug intolerance and
behavior change were found most commonly with
VGB while an aggravation of seizure frequency
occurred in 44% of patients on GBP.
Discussion
This study suggests LTG to be the most effective of
the three add-on therapies in refractory childhood
epilepsy. Significant benefit from the use of LTG as
add-on therapy in childhood epilepsy has been
previously documented but observation periods
have been shorter.2—4 Kluger et al. demonstrated
that after a similar initial efficacy patients with
refractory epilepsies were less likely to be discon-
tinued from LTG than VGB within 5 years.5 Our
study spanning a 10-year period documents a
significant sustained benefit from LTG, which
also appears to have the lowest adverse event
profile of the three anticonvulsants. This is con-
sistent with previous studies identifying this drug
as a safe add-on therapy in refractory childhood
epilepsy.6,7
LTG as add-on therapy was shown to be particu-
larly efficacious in the EE group of patients with
sustained efficacy evident in 32%. This contrasts
with VGB, which proved a useful add-on drug in only
6% and to GBP, which did not show sustained efficacy
in any of the patients in this group. Prospective
studies of LTG therapy in children over shorter
periods have shown efficacy in LGS but have failedto demonstrate superior efficacy for one intractable
treatment group over another.4,7 One retrospective
study of LTG as add-on therapy in children with
refractory epilepsy reported similar findings to ours
with 20% of the Lennox—Gastaut Syndrome group
and 29% of the Myoclonic-astatic group becoming
seizure free.2
The three AEDs studied in this audit were com-
parable in efficacy in partial seizures, with 26%
(VGB), 33% (LTG) and 27% (GBP) suggesting a sus-
tained beneficial effect. GBP has been shown to be
efficacious in partial seizures in children refractory
to other AEDs.8 The order of AED selection in our
study suggests that GBP may be more efficacious
than LTG in partial seizures. A striking finding in our
study was the large percentage of children (44%)
with all seizure types who experienced aggravation
of seizures on GBP. In our study, GBP was prescribed
mainly for partial seizures and 65% of the patients
who experienced seizure aggravation were in this
group. While our results might suggest some benefit
from VGB in refractory partial seizures, reports of
associated visual field defects have had a negative
impact on its use in patients with epilepsy.9,10 Visual
field defects were detected in two of our patients
treated with VGB before concerns regarding visual
field defects were raised.
This study supports previous observations that
LTG has a low adverse event profile with a significant
and sustained long-term benefit in children with
refractory epilepsy including children with epileptic
encephalopathy.References
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